From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从需要说服买家考虑的状态,转变为已获批准、指定、列入、合格、注册、报销或预先授权的选择,进入买家自身的采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得公司未来业务的相当一部分可以在没有每次单独销售事件的情况下到达,并且管理层是否传达了这种准入状态是新的,以至于它所带来的大部分业务量仍将在报告结果之后出现。 在记录中,管理层讨论了SelectQuote的Medicare Advantage分销业务,以及他们正在进行的战略审查。他们提到了“人口健康计划”和“SelectRx”作为亮点。然而,关于公司是否已进入买方的系统(如处方集、网络等)的描述,记录中并没有明确提到。管理层谈论了“SelectRx”的会员增长,但这是公司自己的服务,而不是被纳入外部系统。他们提到“我们相信SelectQuote已经建立了行业最佳平台”,但这是关于平台能力,而非准入状态。 记录中没有任何关于公司被添加到批准供应商名单、处方集、网络或类似系统的描述。管理层谈论了与保险公司的关系,但那是普通的销售关系。他们提到“我们与承运人的关系非常稳固”,但这是常规的。 因此,根据提供的记录,没有证据表明公司最近获得了这种准入状态。答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.